IDEAYA Biosciences, Inc. (IDYA) Enrolls First Patient in Phase 1 Trial of IDE034 Bispecific ADC

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) is among the 10 Fastest Growing NASDAQ Stocks to Buy.

On February 25, 2026, IDEAYA Biosciences, Inc. (NASDAQ:IDYA) announced that the archetypal diligent has been enrolled successful its Phase 1 dose escalation and enlargement proceedings evaluating IDE034, an investigational PTK7/B7H3 bispecific TOP1 ADC. The institution plans to measure the safety, tolerability, and pharmacokinetics of IDE034 arsenic a monotherapy successful the Phase 1 study. It besides intends to trial combinations with agents targeting the DNA harm effect pathway, including its proprietary PARG inhibitor IDE161. Dosing the archetypal diligent with IDE034 triggers a $5M milestone outgo from Ideaya to Biocytogen nether the companies’ enactment and licence agreement.

On February 23, 2026, IDEAYA Biosciences announced the assignment of Theodora Ross to the recently created relation of main improvement officer. In this position, Ross volition pb aboriginal objective improvement for the company’s emerging oncology pipeline and assistance usher its semipermanent probe and improvement strategy. Ross joins Ideaya from AbbVie, wherever she served arsenic VP, caput of aboriginal oncology R&D and tract caput for the Bay Area.

On February 17, 2026, IDEAYA Biosciences reported Q4 gross of $10.88M, compared with statement estimates of $5.95M. Collaboration gross reflected show obligations satisfied done December 31, 2025, related to probe and improvement services recognized implicit clip nether the Servier exclusive licence statement for darovasertib. President and CEO Yujiro Hata said the institution delivered “a beardown 4th of objective execution, objective pipeline enlargement and commercialized readiness activities.” He cited highlights including completion of enrollment of 437 patients successful the OptimUM-02 Phase 2/3 registrational trial, IND submissions for IDE034 and IDE574, and continued enlargement of the company’s U.S. commercialized enactment up of upcoming topline progression-free endurance results.

IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company, discovers and develops targeted therapeutics for diligent populations selected utilizing molecular diagnostics successful the United States.

While we admit the imaginable of IDYA arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 12 Best Tech Stocks that Beat Earnings Estimates and 40 Most Popular Stocks Among Hedge Funds Heading Into 2026

Disclosure: None. Follow Insider Monkey connected Google News.